Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk

C. M. Berlin, S. J. Yaffe

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

A nursing mother with ulcerative colitis was treated with salicylazosulfapyridine (SASP, Azulfidine). Multiple milk samples were collected over a 2-month period. Maternal plasma, saliva, urine and the nursing infant's urine were collected. All fluids were analyzed for SASP and its metabolites. Milk did not contain SASP or its 5-amino salicylate component. Sulfapyridine (SP) and its metabolites were present in milk; the SP level was fairly constant at 3-6 μg/ml. The milk/saliva ratio for SP was 0.81; the milk/plasma ratio for SP was 0.60 and 0.63. Assuming an average milk concentration of 5 μg/ml of SP, the estimated 24-hour secretion (800 cm3 milk) would be approximately 4 mg or 0.3% of maternal dose of SP in the form of SASP. The levels of SP and metabolites determined in random urine samples from the infant were 3-4 μg/ml or a 24-hour excretion of 1.2-1.6 mg (30-40% of the total dose in milk). This exposure did not seem hazardous to this infant.

Original languageEnglish (US)
Pages (from-to)31-39
Number of pages9
JournalDevelopmental Pharmacology and Therapeutics
Volume1
Issue number1
StatePublished - Jan 1 1980

Fingerprint

Sulfapyridine
Sulfasalazine
Human Milk
Milk
Mothers
Urine
Saliva
Nursing
Salicylates
Ulcerative Colitis

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

@article{9d7ccef85c4e43fe98be4728b45bd286,
title = "Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk",
abstract = "A nursing mother with ulcerative colitis was treated with salicylazosulfapyridine (SASP, Azulfidine). Multiple milk samples were collected over a 2-month period. Maternal plasma, saliva, urine and the nursing infant's urine were collected. All fluids were analyzed for SASP and its metabolites. Milk did not contain SASP or its 5-amino salicylate component. Sulfapyridine (SP) and its metabolites were present in milk; the SP level was fairly constant at 3-6 μg/ml. The milk/saliva ratio for SP was 0.81; the milk/plasma ratio for SP was 0.60 and 0.63. Assuming an average milk concentration of 5 μg/ml of SP, the estimated 24-hour secretion (800 cm3 milk) would be approximately 4 mg or 0.3{\%} of maternal dose of SP in the form of SASP. The levels of SP and metabolites determined in random urine samples from the infant were 3-4 μg/ml or a 24-hour excretion of 1.2-1.6 mg (30-40{\%} of the total dose in milk). This exposure did not seem hazardous to this infant.",
author = "Berlin, {C. M.} and Yaffe, {S. J.}",
year = "1980",
month = "1",
day = "1",
language = "English (US)",
volume = "1",
pages = "31--39",
journal = "Developmental Pharmacology and Therapeutics",
issn = "0379-8305",
publisher = "S. Karger AG",
number = "1",

}

Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk. / Berlin, C. M.; Yaffe, S. J.

In: Developmental Pharmacology and Therapeutics, Vol. 1, No. 1, 01.01.1980, p. 31-39.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk

AU - Berlin, C. M.

AU - Yaffe, S. J.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - A nursing mother with ulcerative colitis was treated with salicylazosulfapyridine (SASP, Azulfidine). Multiple milk samples were collected over a 2-month period. Maternal plasma, saliva, urine and the nursing infant's urine were collected. All fluids were analyzed for SASP and its metabolites. Milk did not contain SASP or its 5-amino salicylate component. Sulfapyridine (SP) and its metabolites were present in milk; the SP level was fairly constant at 3-6 μg/ml. The milk/saliva ratio for SP was 0.81; the milk/plasma ratio for SP was 0.60 and 0.63. Assuming an average milk concentration of 5 μg/ml of SP, the estimated 24-hour secretion (800 cm3 milk) would be approximately 4 mg or 0.3% of maternal dose of SP in the form of SASP. The levels of SP and metabolites determined in random urine samples from the infant were 3-4 μg/ml or a 24-hour excretion of 1.2-1.6 mg (30-40% of the total dose in milk). This exposure did not seem hazardous to this infant.

AB - A nursing mother with ulcerative colitis was treated with salicylazosulfapyridine (SASP, Azulfidine). Multiple milk samples were collected over a 2-month period. Maternal plasma, saliva, urine and the nursing infant's urine were collected. All fluids were analyzed for SASP and its metabolites. Milk did not contain SASP or its 5-amino salicylate component. Sulfapyridine (SP) and its metabolites were present in milk; the SP level was fairly constant at 3-6 μg/ml. The milk/saliva ratio for SP was 0.81; the milk/plasma ratio for SP was 0.60 and 0.63. Assuming an average milk concentration of 5 μg/ml of SP, the estimated 24-hour secretion (800 cm3 milk) would be approximately 4 mg or 0.3% of maternal dose of SP in the form of SASP. The levels of SP and metabolites determined in random urine samples from the infant were 3-4 μg/ml or a 24-hour excretion of 1.2-1.6 mg (30-40% of the total dose in milk). This exposure did not seem hazardous to this infant.

UR - http://www.scopus.com/inward/record.url?scp=0018867021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018867021&partnerID=8YFLogxK

M3 - Article

C2 - 6108198

AN - SCOPUS:0018867021

VL - 1

SP - 31

EP - 39

JO - Developmental Pharmacology and Therapeutics

JF - Developmental Pharmacology and Therapeutics

SN - 0379-8305

IS - 1

ER -